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ABSTRACT: 
 
 
The objective of the present study was to 
develop salbutamol sulphate matrix tablets, sustained 
release dosage form, for the treatment of Chronic 
Obstructive Pulmonary Disease (COPD). 
Simultaneous equations were formed to calculate the 
concentration values of Salbutamol sulphate and drug 
compatibility study was performed through Infrared 
spectroscopy. The matrix tablets were prepared by wet 
granulation method using two hydrophobic polymers 
such as Ethyl cellulose and Acrycoat S-100 in varying 
ratios. The granules exhibited satisfactory rheological 
demeanor.  All the seven tablet formulations showed 
acceptable pharmacotechnical properties and complied 
with the in-house specifications for tested parameters. 
The results of formulation F-4 (Ethyl cellulose and 
Acrycoat in 2:1 ratio) could extend the release of 
Salbutamol sulphate up to 12 hr and was found 
comparable to marketed sustained release products. 
Model fitting analysis (Zero order, Higuchi and 
Korsmeyer-Peppas model) for all the formulations 
were performed and it was seen that all the 
formulations predominantly follow the Higuchi model. 
While comparing with the ‘n’ values of all the 
formulations of Korsmeyer-Peppas model, 
Fickian/Diffusion controlled release was observed in 
case of F-4 and F-5, whereas for the other 
formulations non-Fickian transport was observed. 
 
KEYWORDS: Salbutamol sulphate, matrix tablet, 
Ethyl cellulose, Acrycoat, Higuchi model, 
Fickian/Diffusion, Korsmeyer-Peppas model. 
 
 
INTRODUCTION: 
The objective in dosage form design is to 
optimize the delivery of medication so as to achieve a 
measure of control of therapeutic effect in the face of 
uncertain fluctuations in-vivo environment in which 
drug release takes place (1). 
Sustained release dosage forms are designed 
to complement the pharmaceutical activity of the 
medicament in order to achieve better selectivity and 
longer duration of action. Sustained release 
preparations are helpful to reduce the dosage 
frequency and side effects of drugs and improve 
patient’s convenience (2). 
The drug release time can be prolonged 
according to one of the following mechanisms- 
1. Changing the physical properties such as- 
solubility and stability of the drug 
molecules, 
2. Forming a complex of drug molecules with 
ion exchange resins, 
3. Incorporating drug molecules in slowly 
disintegrating or inert porous matrices, 
4. Coating drug molecules with pharmaceutical 
polymers that have a barrier function for the 
diffusion of drug molecules, 
5. Use of  osmotic pumps (3). 
 
Sustained release matrix tablet is relatively easy 
to fabricate by incorporating drug molecules in slowly 
disintegrating or inert porous materials (2). Drug 
release occurs either by diffusion through the matrix 
or by erosion of the matrix or by a combination of 
both diffusion and erosion (4). 
Salbutamol sulphate (SS), a short acting highly 
selective beta 2 adrenoceptor agonist with 
bronchodilating property is widely used for the 
management of Chronic Obstructive Pulmonary 
Disease (COPD) which includes bronchial asthma, 
chronic bronchitis and emphysema (5). SS is almost 
completely absorbed from the gastrointestinal tract 
after oral administration. The reported plasma half-life 
of SS is 2.85±0.85 and the peak plasma concentration 
occurs about 30 minutes after an oral dose. The 
protein binding affinity of SS  7±1% and undergoes 
considerable first pass metabolism. The drug as 
sulphate is soluble in 1 to 4 of water, due to the 
hydrophilic nature it is readily excreted through urine 
(6-9). These bio-pharmaceutical and physicochemical 
properties provide the rationality behind the 
fabrication of SS as a controlled release dosage form. 
SS being basic in nature shows maximum 
absorption in the intestine. The main objective of this 
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work is to deliver the drug as much as possible in 
intact form into the intestine as SS is highly 
susceptible to first pass degradation. Keeping in view 
the hydrophilic character of SS, two hydrophobic 
polymers (Ethyl cellulose and Acrycoat S-100) in 
different ratios are used in this present work as matrix 
forming agent to protect the drug from hepatic 
metabolism. 
Present study concerns with the preparation of SS 
matrix tablet for prolong drug release leading to 
minimization of incidences of nocturnal and early 
morning asthmatic attacks, better patient convenience 
and a pharmacoeconomic novel drug delivery system, 
for effective treatment for of COPD. 
 
Aim:  
Salbutamol sulphate conventional release 
tablets are administered 2 to 4 mg three to four times 
daily and their duration of action are last for 4 to 6 
hours (9). So the aim of this work was to design, 
formulate and develop a novel oral monolithic 
controlled release tablet dosage form that may be 
toiled to provide quasi steady state drug release over 
an extended period of time (10).                     
 
Materials & Methods: 
 
Materials: 
 
Salbutamol sulphate was obtained as a gift 
sample from INGA Laboratories P. Ltd., Mumbai. 
Acrycoat S-100 and Ethyl cellulose (EC) were gift 
samples received from COREL PHARMA-CHEM, 
Gujrat. And S.D. Fine- Chem. Limited, Mumbai, 
respectively. All other chemicals and reagents used 
were obtained from commercial sources and were of 
analytical grade. 
 
Methods 
(2)
: 
 
Compatibility study: 
IR spectra of pure drug, drug and polymers 
and the formulations were obtained using IR 
spectrophotometer (FTIR – 8400S, SHIMADZU) to 
establish the compatibility of ingredients. 
 
Preparation of Matrix Tablet of Salbutamol 
Sulphate:  
Different tablet formulations were prepared 
by wet granulation technique. The compositions of 
each batch of tablet formulation were shown in the 
following Table. 
 
 
All the powders were passed through USP 
100 mesh sieve. Required quantity of drugs, polymers 
and diluents were mixed thoroughly and a sufficient 
quantity of binding agent (0.1% w/v of respective 
polymers in Isopropyl alcohol) was added slowly to 
get dough mass. The mass was sieved through USP 
20/35 mesh and dried at 600C for 1hr. the dried 
granules retained on 35 mesh were mixed with 10% 
fines, 2% Talc and 1% Magnesium Stearate. Tablets 
were compressed using 6 mm round concave punches 
to get the tablets having the hardness between 5 to 7 
kg/ cm2. 
 
EVALUATION OF GRANULES 
(11):
  
1. Measurement of Angle of Repose: 
Angle of repose was determined by funnel 
method. The blend was poured through a funnel that 
can be raised vertically until a maximum cone height 
(h) was obtained. Radius of the heap (r) was measured 
and the angle of repose (θ) was calculated by using the 
formula: 
   θ= tan -1 (h / r) 
This was done thrice, from that average 
angle of repose and standard deviation was calculated. 
 
2. Bulk Density:  
Apparent bulk density (ρb) was measured by 
pouring the pre-weighed (M) blend into a graduated 
cylinder. The bulk volume (Vb) of the blend was 
determined. Then the bulk density was calculated by 
using the formula: 
    ρb =  M / Vb 
This was done thrice, from that average bulk 
density and standard deviation was calculated. 
 
 
3. Tapped Density: 
 
The measuring cylinder containing a known 
mass (M) of blend was tapped for a fixed time, and the 
minimum volume (Vt) occupied in the cylinder was 
measured. The tapped density ρt was calculated by 
using the following formula: 
     ρt = M / Vt 
  This was done thrice, from that average 
tapped density and standard deviation was calculated. 
 
EVALUATION OF THE FORMULATIONS 
(1,12)
 :  
The tablets were evaluated for Appearance, 
Weight variation, Thickness, Diameter, Hardness, and 
Friability to meet the Pharmacopoeial standards. 
 
1. Determination of Weight Variation of the 
tablets: 
 Twenty tablets were selected at random from 
each batch and were weighed accurately and average 
weights were calculated. Then the deviations of 
individual weights from the average weight and the 
standard deviation were calculated. 
 
2. Determination of Thickness and Diameter of 
the tablets: 
Thickness and diameter of ten randomly 
selected tablets from each batch were measured with 
a Slide Calipers. Then the average diameter and 
thickness and standard deviation were calculated.  
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3. Determination of Hardness of the tablets: 
   Five tablets were sampled randomly from 
each batch and the hardness was determined by using 
Monsanto Hardness Tester. Then average hardness 
and standard deviation was calculated. 
 
4. Determination of Friability of the tablets: 
Twenty tablets were sampled randomly from 
each batch and the friability was determined using 
Roche type Friabilator. A pre-weighed tablet sample 
was placed in Friabilator which was then operated for 
100 revolutions (25 rpm). The tablets were then dusted 
and reweighed. Then percentage friability was 
calculated. 
 
5. Determination of Drug Content Uniformity: 
Three tablets were selected randomly from 
each batch and taken separately into three 100 ml 
volumetric flasks. In each flask 100 ml of Phosphate 
buffer pH 6.8 was poured and kept for 24 hrs. After 
filtering the solutions, the absorbance of the filtrate 
was measured at 225 nm. From these absorbances, 
drug content was determined and average and 
standard deviation was calculated. 
 
6. Determination of Mass Degree of Swelling 
(2) 
:  
Each tablet from all formulations were pre-
weighed and allowed to equilibrate with 100 ml of 
water for 5 hrs. Then the tablet was removed, blotted 
using tissue paper and weighed. The Mass Degree of 
Swelling was then calculated by using the following 
formula- 
Q = Mass of swelling gel / Mass of dry the 
powder 
Where,  
Q = Mass Degree of Swelling 
 
7. In-vitro Dissolution Studies of the tablets: 
In-vitro drug release studies were carried out 
using tablet dissolution test apparatus USP Type-I 
(Paddle Type) at 100 rpm. The dissolution medium 
consisted of 900 ml of Phosphate buffer pH 6.8 and 
dissolution carried out for 12 hrs. maintaining the 
temperature at 370C ± 10C. Aliquots of 5 ml were 
withdrawn at 30 minutes intervals and an equivalent 
amount of fresh dissolution media equilibrated at the 
same temperature was replaced. These aliquots were 
filtered and the absorbance of the filtrate was 
measured in each case at about 275 nm against fresh 
pH 6.8 Phosphate buffer solutions as blank. Finally the 
Cumulative percentage of drug release was calculated. 
In-vitro dissolution studies were also carried 
out with the marketed sustained release products 
(ASTHALIN SA-8mg and VENTORLIN 8mg). 
 
 
RESULTS: 
 
TABLE - I. Evaluation of Granules: 
 
Batch 
Code 
Angle of Repose (θ) 
 
Bulk Density (ρb) 
(g/cm
3
) 
Tapped Density (ρt) 
(g/cm
3
) 
 
F – 1 
F – 2 
F – 3 
F – 4 
F – 5 
F – 6 
F – 7 
 
28.2761 ± 0.6635 
26.8946 ± 1.4113 
27.3089 ± 1.4164 
25.1293 ± 1.6721 
27.8269 ± 1.6296 
26.3839 ± 1.3576 
26.2352 ± 0.9686 
 
0.3282 ± 0.0318 
0.3002 ± 0.0106 
0.3158 ± 0.0398 
0.3264 ± 0.0120 
0.2845 ± 0.0253 
0.3072 ± 0.0226 
0.3009 ± 0.0200 
 
0.4524 ± 0.0825 
0.3861 ± 0.0298 
0.4139 ± 0.0758 
0.4186 ± 0.0349 
0.3690 ± 0.0429 
0.3987 ± 0.0502 
0.3861 ± 0.0298 
                           TABLE - II. PHYSICO-CHEMICAL CHARACTERISTICS OF PREPARED TABLETS 
 
Batch 
Code 
Weight Variation Diameter 
Variation 
(mm) 
Thickness 
Variation 
(mm) 
Hardness 
(kg) 
Friability 
(%) 
Drug 
Content 
Uniformity 
(%) 
Mass 
Degree of 
Swelling 
(Q) 
Average Weight 
(mg) 
Highest 
Percentage 
Deviation 
 
F - 1 
 
F - 2 
 
F - 3 
 
F - 4 
 
F - 5 
 
F - 6 
 
 
 
101.15 ±2.54 
 
101.75 ±2.09 
 
101.30 ±2.85 
 
101.45 ±1.90 
 
102.30 ±2.68 
 
101.70 ±2.45 
 
101.70 ±1.84 
 
- 4.10282 
 
-3.6855 
 
5.626851 
 
+ 3.499261 
 
+ 5.571848 
 
+ 5.211406 
 
- 3.63815 
 
6.14±0.13 
 
6.16±0.18 
 
6.21±0.07 
 
6.14±0.13 
 
6.19±0.07 
 
6.22±0.11 
 
6.18±0.12 
 
4.24±0.09 
 
4.22±0.18 
 
4.23±0.13 
 
4.27±0.13 
 
4.25±0.11 
 
4.22±0.08 
 
4.25±0.08 
 
6.0±0.71 
 
6.6±0.55 
 
6.2±0.84 
 
6.2±0.84 
 
6.2±0.45 
 
6.4±0.89 
 
6.4±0.55 
 
0.005 
 
0.00 
 
0.005 
 
0.01 
 
0.00 
 
0.005 
 
0.00 
 
99.67±0.02 
 
99.35±0.02 
 
99.45±0.04 
 
99.37±0.06 
 
99.58±0.04 
 
98.37±0.06 
 
98.69±0.06 
 
1.0583 
 
1.0490 
 
1.0667 
 
1.0505 
 
1.0792 
 
1.1000 
 
1.0769 
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TABLE-III.  In-vitro Dissolution Profile of Formulations (1-7) and Marketed Brands: 
 
Batch 
Code 
Zero Order Higuchi Korsmeyer-Peppas t50 
(hr) 
t77 
(hr) 
X60 
(mg) R
2
 K0 R
2
 KH n K R
2
 
F – 1 
F – 2 
F – 3 
F – 4 
F – 5 
F – 6 
F – 7 
ASTHAL
IN-SA 
VENTOR
LIN 
 
0.8548 
0.8642 
0.8519 
0.8724 
0.8479 
0.8548 
0.8683 
0.9507 
0.9373 
7.0681 
7.1888 
6.7017 
7.3681 
7.2591 
6.9925 
7.1372 
7.5532 
7.4393 
0.9693 
0.9739 
0.9647 
0.9783 
0.9714 
0.9699 
0.9713 
0.9771 
0.9725 
30.0865 
30.2940 
28.1130 
31.8546 
30.6192 
29.5619 
30.0583 
30.5910 
30.2510 
0.6643 
0.6572 
0.5758 
0.5021 
0.4503 
0.6634 
0.6240 
0.4978 
0.4669 
1.2535 
1.5713 
1.9449 
1.5196 
4.4182 
1.2469 
1.2932 
1.4643 
1.500 
0.9904 
0.9932 
0.9842 
0.9948 
0.9932 
0.9860 
0.9901 
0.9956 
0.9945 
2.5 
3.0 
2.5 
2.5 
3.0 
2.5 
3.0 
4.0 
3.5 
5.5 
5.5 
5.5 
6.0 
5.0 
5.5 
5.5 
7.0 
6.5 
32.5149 
32.0090 
32.4507 
32.8142 
31.9739 
32.3314 
32.4315 
30.1446 
32.9453 
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  Figure II. Release Profile of Salbutamol Sulphate 
from Formulation F-1 to F-7. 
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       Figure III. Release Profile of Salbutamol 
Sulphate from Formulation F-1 to F-7
. 
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            Figure IV. Release Profile of Formulation F-
4 and Two Marketed Brand. 
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              Figure V. Release Profile of Formulation 
F-4 and Two Marketed Brand.
DISCUSSION: 
 
The present investigation was undertaken to 
design, formulate and evaluate Salbutamol sulphate 
matrix tablet for sustained release dosage form and 
compare with marketed product. IR study indicated 
good compatibility between drug, polymers and 
excipients.The granules of different formulations were 
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evaluated for Angle of repose, Bulk density and 
Tapped density. The granules indicated good 
flowability with an angle of repose values ranging 
from 25-280. The result of bulk density and tapped 
density are mentioned in Table-I and the results were 
within the limit. 
All tablet formulations were subjected to 
various evaluation parameters and the results obtained 
were within the range. The weight variation test 
indicates that all the tablets were uniform with low 
standard deviation values. The tablet mean diameter 
and mean thickness values ranged from 6.14±0.13 to 
6.21±0.07 mm and 4.22±0.08 to 4.27±0.13 mm, 
respectively. The hardness of all the tablets was within 
a range of 6.0±0.71 to 6.6±0.55 kg/cm2. The loss in 
total weight in friability test was in a range of 0.00 to 
0.01%. The percentage drug content for different 
tablet formulations varied from 98.37±0.06 to 
99.67±0.02% was found to be within the limit. The 
mass degree of swelling was found to be the 
maximum for F–6, indicating high swelling which 
helps in retarding the drug release from the 
formulation.F–4 containing EC and Acrycoat S-100 
(2:1 ratio) was selected as the optimum formulation on 
the basis of the results of in-vitro dissolution studies. It 
is seen that at the end of 12 hr, 98.62% drug was 
released from the formulation, whereas the two 
marketed sustained release products (ASTHALIN-SA 
8mg and VENTORLIN 8mg) released 99.23% and 
99.44%  respectively at the end of 12 hr, which is 
comparable to the fabricated formulation F-4.  
Upon model fitting analysis (Zero order, 
Higuchi and Korsmeyer-Peppas model), it is seen that 
all the formulations predominantly follow Higuchi 
model as the R2 values are near to unity.As compared 
to the ‘n’ value, obtained from the Korsmeyer-Peppas 
model, Fickian/Diffusion controlled drug release is 
observed from F-4 and F-5 whereas for the other 
formulations non-Fickian transport are observed. 
 
 
 
 
CONCLUSION:  
 
From the above results it can be concluded 
that formulation F-4 has achieved the objectives of 
prolonged drug release, patient convenience and cost 
effectiveness as a sustained release dosage form and 
appears to be assessed further by conducting 
bioavailability studies in human volunteers and long 
term stability testing. 
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